Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Argenx Se ADR
(NQ:
ARGX
)
358.41
-7.79 (-2.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Argenx Se ADR
< Previous
1
2
3
Next >
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024
From
argenx SE
Via
GlobeNewswire
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
March 27, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
March 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
March 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
February 29, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
February 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
February 20, 2024
From
argenx SE
Via
GlobeNewswire
5 medical stocks growing earnings by triple digits
February 06, 2024
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Via
MarketBeat
Topics
Economy
Exposures
Economy
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
January 18, 2024
From
argenx SE
Via
GlobeNewswire
argenx Highlights 2024 Strategic Priorities
January 08, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
argenx SE
Via
GlobeNewswire
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
December 20, 2023
From
argenx SE
Via
GlobeNewswire
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
November 28, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
November 16, 2023
From
argenx SE
Via
GlobeNewswire
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
November 01, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
November 01, 2023
From
argenx SE
Via
GlobeNewswire
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
October 24, 2023
From
argenx SE
Via
GlobeNewswire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
September 21, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
September 15, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
August 30, 2023
From
argenx SE
Via
GlobeNewswire
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces closing of global offering
July 24, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces full exercise of underwriters’ option to purchase additional ADSs
July 19, 2023
From
argenx SE
Via
GlobeNewswire
argenx raises $1.1 billion in gross proceeds in a global offering
July 18, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces launch of proposed global offering
July 17, 2023
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.